Fundraising Fox
Alveogene
Founded 2022 · 4 employees on LinkedIn · 1 known investors
Find your way into Alveogene
169 people in our graph share verified history with the Alveogene team — schools, employers, funds. One of them is your warm intro.
Frank Bulensunlockedknows David Hipkiss · together at Prosonix Ltd (overlapped)
knows the team · via Alveogene
×6knows the team · via Air Products plc
×4knows the team · via University of Birmingham
AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
Founders & leadership
DH
David HipkissExecutive ChairDavid Hipkiss is Executive Chair of AlveoGene, a respiratory gene therapy company. He has held senior leadership roles including Chair and CEO positions across pharmaceutical and biotech companies over three decades, with experience in corporate development, fundraising, and commercialization of biotech platforms.
Investors · 1
Oxford Science Enterpriseslisted by Oxford Science EnterprisesOxford · $63.5K – $31.8M
How we know: Oxford Science Enterprises's portfolio page · a partner's Signal profile · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- ALVEOGENE LIMITED
- Company number
- 14342459
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Sept 2022
- Registered office
- C/O Oxford Science Enterprises, 46 Woodstock Road, Oxford, OX2 6HT
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 6 Sept 2025 · next due 20 Sept 2026
Current officers · 5
- Eric Walter Frederick Wolfgang Alton — director, appointed 7 Sept 2022
- Claire Brown — director, appointed 24 Jul 2023
- David John Hipkiss — director, appointed 24 Jul 2023
- Alistair James Mcdermott — director, appointed 11 Jul 2025
- John Rice — director, appointed 24 Jul 2023
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Alveogene do?
- AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
- Who are Alveogene's investors?
- Alveogene's investors include Oxford Science Enterprises.